Get started
Author

Lear Matapure

Mapping the human genetic architecture of COVID-19
2021 · COVID-19 Host Genetics Initiative, COVID-19 Host Genetics InitiativeLeadership, et al. · Nature · 983
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Eugenia Abaleke, Mustafa Abbas, et al. · The Lancet · 533
PDF
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 493
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 369
Whole-genome sequencing reveals host factors underlying critical COVID-19
2022 · Athanasios Kousathanas, Erola Pairo-Castineira, et al. · Nature · 326
PDF
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 324
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 290
GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19
2023 · Erola Pairo-Castineira, Konrad Rawlik, et al. · Nature · 224
PDF
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · Obbina Abani, Ali Abbas, et al. · The Lancet · 129
A second update on mapping the human genetic architecture of COVID-19
2023 · The COVID-19 Host Genetics Initiative, Leadership, et al. · Nature · 118
PDF
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
2022 · Simeng Lin, Nicholas A. Kennedy, et al. · Nature Communications · 96
PDF
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41
PDF
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39
PDF
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
2022 · Zhigang Liu, Kaixing Le, et al. · ˜The œLancet. Gastroenterology & hepatology · 36
Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases · 12
PDF
Stratified analyses refine association between TLR7 rare variants and severe COVID-19
2024 · Jannik Boos, Caspar I. van der Made, et al. · Human Genetics and Genomics Advances · 12
PDF
Author Correction: GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19
2023 · Erola Pairo-Castineira, Konrad Rawlik, et al. · Nature · 9
PDF
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer
2025 · Gianmarco Leone, Francesco Orlando, et al. · JAMA Oncology · 5
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O. Abani, A. Abbas, et al. · EClinicalMedicine · 5
Mapping the human genetic architecture of COVID-19
2021 · Niemi, Mari E. K., Karjalainen, Juha, et al. · Research at the University of Copenhagen (University of Copenhagen) · 5
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases
PDF
Works count: 22
Citation count: 4,048
H-index: 14
I10-index: 16
Year
Topic
Type